Physician profile
Thomas B Freeman
NPI 1962421297
$123,793.05
in general payments reported to CMS, 2019-2025
13 companies · $16K in 2025
The $16K reported for 2025 was more than what 88% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $22K · 2021: $17K · 2022: $20K · 2023: $15K · 2024: $15K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $45K · Consulting Fee: $1,125 · Food and Beverage: $88.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $45,000.00 |
| Consulting Fee | $1,125.00 |
| Food and Beverage | $88.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $75,000.00 | 2021-2025 | Activa Pc |
| Medtronic USA, INC. | $30,916.07 | 2019-2020 | |
| Ctl Medical Corporation | $8,772.10 | 2019-2020 | |
| Tenon Medical, INC. | $3,500.00 | 2022 | |
| Novo Nordisk INC | $3,375.00 | 2021-2022 | |
| Sivantage, INC. | $1,153.76 | 2023-2025 | |
| Depuy Synthes Sales INC. | $372.91 | 2019-2023 | Fibergraft Aeridyan Matrix, Vivigen Mis Delivery System, Teligen |
| Si-Bone, INC. | $224.71 | 2019-2020 | |
| Spinesource, INC. | $186.31 | 2022 | |
| Alphatec Spine, INC | $157.12 | 2021 | |
| Orthofix Medical, INC. | $123.46 | 2019 | |
| Pfizer INC. | $11.61 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.